Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

25P-NBOMe

This article is a stubmissing:
Subjective Effects
Pharmacology
Tolerance
History & Culture
25P-NBOMe molecule structure25P-NBOMe molecule structure
2C-P-NBOMe
NBOMe-2C-P
Psychoactive Class
PsychedelicHallucinogen

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold100-250 µg
Light250-450 µg
Moderate450-700 µg
Strong700-1500 µg
Heavy1500+ µg

Duration

Onset25-40 minutes
After Effects1-16 hours
Total7-14 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacology not written up yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AMTLithiumPregabalin

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

AmphetaminesCocaineDXMTramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE
Powered by TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Toxicity

Lethal Dosage

No lethal-dose or LD50 data were identified. Available descriptions characterize 25P-NBOMe as a rare, potent psychedelic with risks similar to other NBOMe compounds.

History & Culture

History & Culture not written up yet

Legality

By Country

Illegal1
United Kingdom flagUnited KingdomIllegal

References

Source Pages

  1. Bluelight: The Small & Handy 25P-NBOMe Thread
  2. Erowid: 25P-NBOMe Experience Report
  3. Wikipedia
  4. Wikipedia: 2C-P-NBOMe

Citations

  1. PubChem CID 118796470 Synonyms. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/118796470/synonyms/JSON1
  2. PubChem 25P-NBOMe Chemical Properties. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/25P-NBOMe/property/IUPACName,Title,MolecularFormula/JSON1
  3. Misuse of Drugs Act 1971, Schedule 2 Part I paragraph 1(c). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/11
  4. Misuse of Drugs Act 1971, section 5. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/section/51
  5. The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014, article 1. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2014/1106/article/1/made1
  6. The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014, article 3. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2014/1106/article/3/made1
  7. The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014, Explanatory Note. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2014/1106/note/made1

Further Reading

  1. Casale & Hays (2012) - Characterization of 11 NBOMe Derivatives (DEA Microgram Journal)
  2. ChemSpider: 25P-NBOMe Chemical Structure Data
  3. EMCDDA: Europol (2023) - NBOMe Compounds Analytical Data
  4. Hansen et al. (2014) - Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines
  5. Luethi & Liechti (2018) - Monoamine Transporter and Receptor Interaction Profiles
  6. Rickli et al. (2015) - Receptor Interaction Profiles of NBOMe Derivatives
  7. Zawilska et al. (2020) - NBOMes: Highly Potent and Toxic Alternatives of LSD

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 25P-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.